The US Food and Drug Administration (FDA) has approved the use of Corona resistant pills by US multinational pharmaceutical company Mark. This drug can only be used to treat people at high risk after a corona infection. News AFP
The FDA approved Mark’s Corona pill on Thursday. Pfizer’s Corona pill Paxlovid was approved by the regulator yesterday.
Mark’s oral corona pill Malnupiravi is known as ‘MSD’ outside the United States and Canada. This medication is usually taken within five days of the onset of corona symptoms. Studies have shown that the drug can reduce hospitalization and mortality in high-risk patients by 30 percent after coronavirus infection.
The FDA says Mark’s pill should not be taken by anyone under the age of 18. The approval did not match even in the case of pregnant women. However, the doctors will be able to decide the use of the drug on them considering the situation.
Examination of Pfizer’s pills showed that it reduced the risk of coronary heart disease and death by 6 percent. However, no one under the age of 12 can take this pill.
Meanwhile, the FDA has said that Mark and Pfizer pills are not a substitute for Tika. This medicine taken orally will work as a helper against corona.
James Amato is an expert in the technology industry and a respected journalist who covers technology, lifestyle, and healthcare. He has a wealth of knowledge and experience in the technology sector, and is known for his ability to analyze and report on the latest trends and developments in the industry.
Amato has a unique perspective on technology’s impact on our daily lives, and his writing focuses on how technology is shaping our society, including healthcare and lifestyle. He has a degree in computer science and a master’s degree in journalism. He has worked for reputed publications. Amato is a thought leader in the technology industry, and his articles are widely read and respected for their in-depth analysis and insightful commentary. He is also a regular speaker on technology and healthcare at various conferences and events.
Email: [email protected]
Address: 10397 217th Place Northeast, Arlington, WA 98223 USA
Contact number: 451-343-5468